Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument
dc.contributor.author | Khanna, Dinesh | en_US |
dc.contributor.author | Hays, Ron D. | en_US |
dc.contributor.author | Maranian, Paul | en_US |
dc.contributor.author | Seibold, James R. | en_US |
dc.contributor.author | Impens, Ann | en_US |
dc.contributor.author | Mayes, Maureen D. | en_US |
dc.contributor.author | Clements, Philip J. | en_US |
dc.contributor.author | Getzug, Terri | en_US |
dc.contributor.author | Fathi, Nihal | en_US |
dc.contributor.author | Bechtel, Amber | en_US |
dc.contributor.author | Furst, Daniel E. | en_US |
dc.date.accessioned | 2009-10-02T16:56:33Z | |
dc.date.available | 2010-10-05T18:27:29Z | en_US |
dc.date.issued | 2009-09-15 | en_US |
dc.identifier.citation | Khanna, Dinesh; Hays, Ron D.; Maranian, Paul; Seibold, James R.; Impens, Ann; Mayes, Maureen D.; Clements, Philip J.; Getzug, Terri; Fathi, Nihal; Bechtel, Amber; Furst, Daniel E. (2009). "Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument." Arthritis & Rheumatism 61(9): 1257-1263. <http://hdl.handle.net/2027.42/64108> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/64108 | |
dc.description.abstract | Objective To refine the previously developed scleroderma (systemic sclerosis [SSc]) gastrointestinal tract (GIT) instrument (SSC-GIT 1.0). Methods We administered the SSC-GIT 1.0 and the Short Form 36 to 152 patients with SSc; 1 item was added to the SSC-GIT 1.0 to assess rectal incontinence. In addition, subjects completed a rating of the severity of their GIT involvement (from very mild to very severe). Evaluation of psychometric properties included internal consistency reliability, test–retest reliability (mean time interval 1.1 weeks), and multitrait scaling analysis. Results Study participants were mostly women (84%) and white (81%); 55% had diffuse SSc. Self-rated severity of GIT involvement ranged from no symptoms to very mild (39%), mild (21%), moderate (31%), and severe/very severe (9%). Of an initial 53 items in the SSC-GIT 1.0, 19 items were excluded, leaving a 34-item revised instrument (the University of California, Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 [UCLA SCTC GIT 2.0]). Analyses supported 7 multi-item scales: reflux, distention/bloating, diarrhea, fecal soilage, constipation, emotional well-being, and social functioning. Test–retest reliability estimates were ≥0.68 and coefficient alphas were ≥0.67. Participants who rated their GIT disease as mild had lower scores on a 0–3 scale on all 7 scales. Symptom scales were also able to discriminate subjects with corresponding clinical GIT diagnoses. The Total GIT Score, developed by averaging 6 of 7 scales (excluding constipation), was reliable and provided greater discrimination between mild, moderate, and severe self-rated GIT involvement than individual scales. Conclusion This study provides support for the reliability and validity of the UCLA SCTC GIT 2.0, an improvement over the SSC-GIT 1.0, and supports a Total GIT Score in SSc patients with GIT. | en_US |
dc.format.extent | 85771 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Scleroderma Program, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan Scleroderma Program, Ann Arbor | en_US |
dc.contributor.affiliationother | University of California, Los Angeles ; Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, 1000 Veteran Avenue, Room 32-59, Rehabilitation Building, Los Angeles, CA 90095 | en_US |
dc.contributor.affiliationother | University of California, Los Angeles, and RAND Corporation, Santa Monica, California | en_US |
dc.contributor.affiliationother | University of California, Los Angeles | en_US |
dc.contributor.affiliationother | University of Texas, Houston ; Dr. Mayes has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis and United Therapeutics, and (more than $10,000) from Actelion. | en_US |
dc.contributor.affiliationother | University of California, Los Angeles | en_US |
dc.contributor.affiliationother | University of California, Los Angeles | en_US |
dc.contributor.affiliationother | Assiut University Hospital, Assiut, Egypt | en_US |
dc.contributor.affiliationother | University of California, Los Angeles | en_US |
dc.contributor.affiliationother | University of California, Los Angeles | en_US |
dc.identifier.pmid | 19714600 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/64108/1/24730_ftp.pdf | |
dc.identifier.doi | 10.1002/art.24730 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.